Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics,Immunity, Inflammation and Disease

当前位置： X-MOL 学术 › Immun. Inflamm. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics
Immunity, Inflammation and Disease ( IF 3.1 ) Pub Date : 2021-05-07 , DOI: 10.1002/iid3.434
Andreas Renner ₁ , Katharina Marth ₁ , Karin Patocka ₁ , Marco Idzko ₂ , Wolfgang Pohl ₁

Affiliation

Dupilumab is a monoclonal antibody against the IL-4 receptor alpha which has shown efficacy in T2 high severe asthmatics in phase 3 randomized controlled trials. The purpose of this real-life study is to demonstrate the real-life effectiveness of dupilumab in Austrian severe asthma patients. We retrospectively analyzed all patients receiving dupilumab at our severe asthma clinic. Thirteen patients have so far received dupilumab at our center. The primary outcome, asthma control questionnaire 6-item scale at 2 weeks, improved by 0.57 points (p = .014), which is statistically and clinically significant. Similarly, the asthma control test at 4 weeks improved by 3.91 points (p = .024), also statistically and clinically significant. Improvements in forced expiratory volume in 1 s at 2 weeks were neither statistically, nor clinically significant. Improvements at 4 weeks (+220 ml, p = .041), and 3 months (+229 ml, p = .006), were statistically significant and clinically borderline significant. No severe adverse events or hypereosinophilia were observed. No adverse events led to treatment discontinuation. Most patients (85%) had previously received monoclonal antibody treatment for severe asthma. Previous monoclonal antibody treatment had been discontinued in these patients due to a lack of clinical response. Dupilumab is effective and safe in Austrian real-life severe asthmatics. It provides a possible treatment strategy for T2 high severe asthmatics who do not qualify for anti-immunoglobulin E or anti-IL5/IL5R monoclonal antibody treatments or do not adequately respond to these.

中文翻译：

Dupilumab 迅速改善主要抗 IL5/IL5R 预处理的奥地利现实生活中严重哮喘患者的哮喘控制

Dupilumab 是一种针对 IL-4 受体 α 的单克隆抗体，在 3 期随机对照试验中已显示出对 T2 重度哮喘患者的疗效。这项真实生活研究的目的是证明 dupilumab 在奥地利严重哮喘患者中的真实疗效。我们回顾性分析了在我们的重度哮喘诊所接受 dupilumab 治疗的所有患者。迄今为止，我们中心已有 13 名患者接受了 dupilumab 治疗。主要结果，哮喘控制问卷 6 项量表在 2 周时提高了 0.57 分 ( p = .014)，具有统计学意义和临床意义。同样，第 4 周的哮喘控制测试提高了 3.91 分（p = .024)，同样具有统计学意义和临床意义。2 周时 1 秒内用力呼气量的改善既没有统计学意义，也没有临床意义。4 周（+220 ml，p = .041）和 3 个月（+229 ml，p = .006)，具有统计学意义和临床临界意义。没有观察到严重的不良事件或嗜酸性粒细胞增多症。没有不良事件导致治疗中断。大多数患者 (85%) 之前曾因严重哮喘接受过单克隆抗体治疗。由于缺乏临床反应，这些患者之前的单克隆抗体治疗已停止。Dupilumab 对奥地利现实生活中的严重哮喘患者有效且安全。它为不符合抗免疫球蛋白 E 或抗 IL5/IL5R 单克隆抗体治疗资格或对这些药物没有充分反应的 T2 高危哮喘患者提供了一种可能的治疗策略。

更新日期：2021-05-07

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文